Clinical Trial Patient Technology Articles

1. eCOA Solutions: Trends, Benefits, & Buying In 2024 2/22/2024

   The eCOA solution market is anticipated to capture $15.1 billion by the year 2036, growing at a CAGR of almost 15.1% during the forecast period. Learn more with this market outlook.

2. Embracing Hybrid Trial Design — How, When, & Why To Use It 6/28/2023

   Global Clinical Sciences & Operations Innovation Lead Lewis Millen talks about UCB’s approach to hybrid trial design, how and when it chooses to implement remote and virtual elements, and why a hybrid trial is beneficial to both the sponsor and the patient.

3. How PROs Enhance Patient Care Decisions And Future Clinical Research 6/12/2023

   Patient-reported outcomes (PROs) offer unique insights that complement traditional treatment efficacy endpoints, such as survival or disease relapse, and can facilitate better discussions between clinicians and patients. When PROs are incorporated into clinical trial protocols, sponsors can gain a better understanding of the treatment’s impact from the patient’s perspective. 

4. The 5Vs Of Collecting Clinical Data 1/26/2023

   Not all data is created equal. Our data strategies need to be commensurate with the risks, complexity, and value of the data collected. If the true value of data is to be realized, it must be collected and captured in accordance with the five “V” dimensions: volume, variety, velocity, veracity, and value.

5. Two Straightforward Ways To Improve DE&I In Clinical Trials 12/27/2022

   We don’t have to wait for federal guidance, additional DHT, or new innovations. We have the tools to begin to address the lack of trust and limited data and incorporate them into diversity plans for clinical trials today. Here's how.

6. Boehringer Ingelheim Implements One Medicine Technology Platform 12/8/2022

   For years, Boehringer Ingelheim operated with a system comprised of best-of-breed solutions from different vendor companies. After carefully evaluating the technology environment, the company decided to move from best-of-breed solutions to an end-to-end product development platform.

7. What Your Sites Love And Hate About DCTs 10/25/2022

   For years, sponsor companies have had access to new and emerging technologies that would ease the participation burden of patients in clinical trials. While these emerging technologies helped sponsor companies keep their trials on track, they have also been a burden for the clinical sites having to deal with the changes required to keep up with them. Do you know where your sites stand on the adoption of hybrid trials and DCTs?

8. FDA Seeks Comment On Fit-For-Purpose COAs Guidance 7/14/2022

   On June 29, the FDA released the new guidance, Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. This article sums up the guidance and explains the four types of COAs that the FDA prefers (PROs, ObsROs, ClinROs, and PerfOs). Submit comments to the FDA by September 28, 2022.

9. What Does The Future Hold For Decentralized Clinical Trials? 4/20/2022

   What can we expect to see from decentralized trials in the next three years, and what are the challenges sponsor companies will need to overcome? A webinar hosted by IBM Watson hoped to answer that question and many others.

10. Best Practices For Designing Patient-Centric Decentralized Clinical Trials 4/12/2022

    Decentralized clinical trials are not universally applicable to all phases of a trial and therapeutic areas. The recommendations in this article may bring decentralized and hybrid trials to a more tangible and realistic view and, in essence, make them more executable.